Viatris Inc. (NASDAQ: VTRS) announced that its phase 3 study of MR-139 for blepharitis did not meet its primary endpoint ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE